12-02-2007- In association with the The Department for Metahuman Affairs, the United States congress approves 1.4 billion dollars for Metahuman research and development with the express purpose of investigating a way that PMPD may be utilized for military based technologies. Of the hundreds of bids received, Raytheon Technologies Corp., UnitedHealth Inc., and Humana Inc. all succeeded in acquiring funding. Raytheon Technologies Corp begins work on Codename Project Pygmalion.
B. RESEARCH AND DEVELOPMENT
The basis of Raytheon's research stemmed from a PMPD affected individual hereby referred to as 'Patient Zero.'1 Patient Zero's PMPD manifestation increased skeletal robusticity, muscular mass, reaction times, and overall toughness. Patient Zero was noted as incredibly mentally unstable and frequently attacked Raytheon staff and researchers. Raytheon focused Project Pygmalion on replicating Patient Zero's PMPD manifestation into unaffected individuals. A 'super soldier' project. However, At 12:01 PM, 02-13-2008, Patient Zero was neutralized in an act of self-defense by researcher [REDACTED].
To preserve and replicate Patient Zero's abilities, his pituitary gland and thyroid were recovered and pieces of it grafted into various plant species. The intended effect was that the grafted plants, yams, soybean plants, and various mushroom species, would be able to replicate some of the abnormalities in at least a small part. To the surprise of Raytheon researchers, one graft proved exceptionally promising. In an unknown reaction with the PMPD-affected organs, a cordyceps fungal specimen not only accepted the organ graft but also began reproducing it with perfect chemical accuracy.
10-07-2010- After perfecting the reproduction process, Raytheon begins acquiring both PMPD and non-PMPD undesirables from the foster care system with the assistance of the newly established Metahuman Incident Response Agency. These subjects are used as tests for the efficacy and survival rating of artificially grafted PMPD hormones. First starting with individuals already affected with PMPD, then to those unaffected. Initial tests proved promising with a 95% survival rating.
04-01-2015- The primary cordyceps fungal specimen begins to show signs of degradation and attempts to replicate and revive the mycelium begin. Grafting non-PMPD affected individuals with grown pituitary glands and grown thyroids begin, initial results are promising, but inconsistent.
12-17-2018- All individuals begin to show signs of degradation in mental states, degradation of physical abilities, and increased violent tendencies. New graftings approach a failure rate of 50%. Older test subjects finishing puberty begin to lose their abilities. Raytheon requests additional funding from Congress.
01-01-2023- The cordyceps fungal specimen, despite all attempts to revive and replicate, dies. All individuals with artificial hormones, grown organs, and any association with the specimen immediately begin to present adverse effects. Approximately 95% die within six months.
08-01-2023- Project Pygmalion is officially considered a failure. All dead subjects, research, and dead fungal specimens are ordered to be destroyed. Attempting to save money, independent contractor Barry's Burning is hired to incinerate all research. The incinerator in possession of Barry's Burning was reportedly broken at the time he accepted the contract, so all research and bodies were placed into a large pit and burned openly into the air. Raytheon was made aware of this breach of contract when police were called to the site of the burning.
08-10-2023- Raytheon security, in partnership with MIRA, issued a gag order on all officers involved in investigating the open burn pit. The families of the owner and employees of Barry's Burning were paid $50,000 each in exchange for not filing any wrongful death lawsuits. MIRA assumes control of the recovered asset from the burn site.
C. PROJECT RESULTS
Project Pygmalion is considered, by and large, a failure. No individual grafted with either artificially grown organs or artificially produced hormones both survived and retained their abilities. The recovered test subject, codenamed 'Mycelia,' is not considered a success as their creation cannot be replicated in any manner. However, reluctant to present Congress with absolutely nothing, Raytheon donates product 'Mycelia' to the Metahuman Incident Response Agency and trades all involved researchers to Humana Inc.
The burn site, hereto referred to as 'Area 103,' has been sectioned off as a toxic waste spill. All locals living in the nearby town of 'FieldSpring' have been evacuated and told they cannot return to their homes. Area 103 is available as a research site to anyone with appropriate MIRA clearance, but the site has been largely taken over by MIRA as Raytheon has stepped away from the project entirely.
1. Patient Zero, contrary to the name, is not supposed as the origin of PMPD.